Alogliptin Showed Influence towards the Activity of Drug-Metabolizing Enzymes (DMEs)

Alogliptin is an anti-diabetic drug clinically utilized under the trade name Nesina in the USA and Vipidia in Europe, and this study aims to determine the inhibition of alogliptin on the activity of one of the important drug-metabolizing enzymes (DMEs) UDP-glucuronosyltransferases (UGTs). In vitro incubation mixture was used to evaluate the inhibition of alogliptin on UGT1A1, -1A3, and -1A9. 100 uM of alogliptin was used as the initial screening concentration. Alogliptin showed significant inhibition towards UGT1A1 (p < 0.05). Alogliptin 100 mu M did not exert influence towards the activity of UGT1A3 and UGT1A9. In conclusion, potential drug-drug interaction (DDI) existed between alogliptin and drugs undergoing UGT1A1-catalyzed metabolism.